Pfizer cuts full-year outlook due to declining sales of Covid-19-related products
Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion. Falling sales of both clipped sales in the second quarter, but…
#pfizer #moderna #newyorkcity #pfizerinc #jpmorgan